文献速递消化系统肿瘤

晚期胃癌患者生活质量与疾病特征及治疗结局的关联:RAINBOW与REGARD III期试验的探索性分析

Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials.
PubMed 文献 · Eur J Cancer · 2018-12-14

该研究汇总了RAINBOW与REGARD两项III期试验中经治胃癌或胃食管结合部癌患者的生活质量数据,采用EORTC QLQ-C30量表探索生活质量与肿瘤缓解、疾病可测量性及体力状态等临床特征的关联。结果显示疾病进展导致所有功能量表、整体生活质量及症状量表评分恶化,整体生活质量和功能量表评分变化15-20分可预测肿瘤状态变化,较小变化(5-15分)可预测体力状态变化。

要点

  • 基线生活质量数据可获取者共989例,乏力、疼痛和食欲减退为突出基线症状。
  • 疾病进展导致所有功能量表(p<0.0001至p=0.0306)、整体生活质量(p=0.0011)及症状量表评分恶化。
  • 整体生活质量和功能量表评分变化15-20分可预测肿瘤状态变化,较小变化(5-15分)可预测体力状态变化。

核心结论

  • 研究强调疾病控制对维持或改善生活质量的重要性,数据可能改进未来试验设计及经治胃癌患者的常规临床照护。

研究设计与样本

  • 汇总RAINBOW与REGARD两项III期试验中经治胃癌或胃食管结合部癌患者的生活质量数据,两项研究均使用EORTC QLQ-C30量表。
  • 采用多变量逻辑回归估计QLQ-C30评分从基线至第6周的变化对临床结局的预测作用,采用方差分析估计临床状态变化对生活质量的影响。

主要发现

  • 基线生活质量数据可获取者共989例,乏力、疼痛和食欲减退为突出基线症状。
  • 疾病进展导致所有功能量表评分恶化(p<0.0001至p=0.0306)、整体生活质量恶化(p=0.0011)及症状量表评分恶化:乏力p<0.0001、恶心/呕吐p=0.0007、疼痛p=0.0052、食欲减退p=0.0061。
  • 体力状态恶化时生活质量也呈现相似趋势。
  • 整体生活质量和功能量表评分变化15-20分可预测肿瘤状态变化,乏力、疼痛和食欲减退评分变化同样可预测肿瘤状态变化。
  • 较小生活质量变化(5-15分)可预测体力状态变化;无论基线疾病是否可测量,结果相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inadequate understanding of interpretation of quality of life (QoL) instruments leads to unsatisfactory data reporting and clinical decision-making, including in gastric cancer care. MATERIALS AND METHODS: Pooled QoL data from two phase III studies of ramucirumab with or without paclitaxel in previously treated patients with gastric or gastroesophageal junction cancer were used to explore associations with clinical attributes, including tumour response, disease measurability and performance status (PS). The European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ)-C30 was used in both studies. Changes in QLQ-C30 scores from baseline to week 6 as a predictor of clinical outcomes and impacts of changes in clinical status on QoL were estimated by multivariate logistic regression and analyses of variance, respectively. RESULTS: Baseline QoL data were available for 989 patients. Fatigue, pain and appetite loss were prominent baseline symptoms. Disease progression resulted in worse QoL in all functional scales (p < 0.0001 to p = 0.0306), global QoL (p = 0.0011) and symptom scales (fatigue, p < 0.0001; nausea/vomiting, p = 0.0007; pain, p = 0.0052; appetite loss, p = 0.0061). Similar trends were seen with deterioration of PS on QoL. A 15- to 20-point change in global QoL and functional scale scores predicted change in tumour status as did change in fatigue, pain and appetite loss scores. Smaller QoL changes (5-15 points) predicted PS change. Results were similar in patients regardless of baseline disease measurability. CONCLUSIONS: Our study underscores the importance of disease control for maintaining or improving QoL. These data could improve future trial design and routine clinical care for patients receiving therapy for previously treated gastric cancer. NCT00917384, NCT01170663.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Chau I, Fuchs CS, Ohtsu A, et al. Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials. Eur J Cancer. 2018. PMID: 30557792. doi:10.1016/j.ejca.2018.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。